Cite
HARVARD Citation
Morishima, C. et al. (2015). CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].